• Adamas Pharmaceuticals Inc., of Emeryville, Calif., reported that the company's Phase II/III EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) trial of ADS-5102 (Nurelin, amantadine HCl extended release) met the primary endpoint, defined as the reduction in levodopa-induced dyskinesia in Parkinson's patients over eight weeks compared to placebo, as measured by the Unified Dyskinesia Rating Scale.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST